Idorsia

Kalender

	Est. tid*
2026-07-30	-	Kvartalsrapport 2026-Q2
2026-05-06	-	Årsstämma
2026-02-26	-	Bokslutskommuniké 2025
2025-07-30	-	Kvartalsrapport 2025-Q2
2025-05-28	-	Årsstämma
2025-02-27	-	Bokslutskommuniké 2024
2024-07-25	-	Kvartalsrapport 2024-Q2
2024-06-13	-	Årsstämma
2024-02-06	-	Bokslutskommuniké 2023
2023-07-25	-	Kvartalsrapport 2023-Q2

Beskrivning

Land	Schweiz
Lista	86

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Filter

År

Typ

Språk

Rensa

2026-11-03 07:00:00 Invitation to Idorsia's webcast and conference call to provide more context on the opportunity and launch approach for TRYVIO/JERAYGO

2026-10-29 07:00:00 Idorsia reports accelerating QUVIVIQ growth, advances key value drivers, and reaffirms full-year financial guidance 4,58 CHF | -0,15% | 0,10 MCHF

2026-10-29 06:30:00 Idorsia and SPV investors partner to unlock the blockbuster potential of TRYVIO/JERAYGO with a targeted launch in specialists 4,58 CHF | -0,15% | 0,10 MCHF

2026-10-28 07:00:00 Idorsia initiates pivotal Phase 3 study for lucerastat in Fabry disease and enters co-development and commercialization agreement with Nxera 4,58 CHF | +1,62% | 0,03 MCHF

2026-10-27 07:00:00 Idorsia seeks US label update for QUVIVIQ daytime functioning benefits – first patients enrolled in Dari-Dream 4,51 CHF | +4,47% | 0,08 MCHF

2026-10-26 07:00:00 A new scientific avenue for daridorexant: Idorsia to advance development in autism spectrum disorder 4,32 CHF | +2,54% | 0,08 MCHF

2026-10-23 17:45:00 Idorsia presents outstanding results with daridorexant in children and adolescents with insomnia and an expanding body of evidence in adults at Sleep Europe 2026 4,21 CHF | +0,10% | 0,15 MCHF

2026-10-12 07:00:00 Aprocitentan efficacy data reinforce endothelin pathway blockade as a distinct therapeutic approach across the cardiometabolic disease spectrum including obesity 4,40 CHF | +6,27% | 0,24 MCHF

2026-10-08 17:45:00 New results across pediatric, adult and real-world insomnia settings highlight the expanding clinical evidence for daridorexant at Sleep Europe 2026 4,08 CHF | -4,58% | 0,16 MCHF

2026-10-05 17:45:00 Efficacy of aprocitentan in patients across the cardiometabolic disease spectrum including obesity to be presented at AHA Hypertension 4,42 CHF | -1,73% | 0,22 MCHF

2026-08-11 07:00:00 Idorsia acknowledges the DEA proposal to reclassify dual orexin receptor antagonists to the lowest schedule – Schedule V 6,42 CHF | +9,18% | 1,75 MCHF

2026-07-27 07:00:00 Idorsia advances global rollout of QUVIVIQ with Jamjoom Pharma partnership in Saudi Arabia and the Levant 6,62 CHF | +8,70% | 2,08 MCHF

2026-07-23 18:00:00 Invitation to Idorsia's HY 2026 Financial Reporting webcast and conference call 6,11 CHF | -2,63% | 0,68 MCHF

2026-07-01 07:00:00 Idorsia appoints Roland Wandeler as Chief Executive Officer 6,53 CHF | -5,67% | 3,49 MCHF

2026-06-26 07:00:00 Idorsia confirms successful closing of Pharmakon loan agreement and full repayment of New Money Facility 6,74 CHF | +11,92% | 5,27 MCHF

2026-06-09 07:00:00 Idorsia strengthens financial position with up to CHF 250 million loan from Pharmakon 4,44 CHF | +4,08% | 1,23 MCHF

2026-06-01 07:05:00 Idorsia reports new positive results with its breakthrough C. difficile vaccine – underscoring the unique potential of its glycan technology 4,39 CHF | -1,59% | 1,06 MCHF

2026-06-01 07:00:00 New analysis of Idorsia’s aprocitentan demonstrates significant and sustained reduction in albuminuria in patients with uncontrolled / resistant hypertension 4,39 CHF | -1,59% | 1,06 MCHF

2026-05-06 16:44:24 Shareholders vote in favor of all proposals by the Board at Idorsia’s Annual General Meeting 2026 3,68 CHF | -1,23% | 0,74 MCHF

2026-04-28 07:00:00 Idorsia reports strong Q1 2026 performance with 74% QUVIVIQ sales growth year-on-year 3,88 CHF | +3,57% | 3,33 MCHF

2026-04-10 07:00:00 Idorsia issues invitation to the 2026 Annual General Meeting of Shareholders 3,50 CHF | +1,60% | 0,67 MCHF

2026-04-09 07:00:00 Idorsia welcomes Amer Joseph as new Chief Medical Officer and Head of Global Clinical Development 3,44 CHF | -1,99% | 0,94 MCHF

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode